Anikilozlovchi spondiloartritda matriks metalloproteinaza  9-turining davo negizida o’zgarishi

Please use this identifier to cite or link to this item: http://repo.tma.uz/xmlui/handle/1/2344

Full metadata record

DC Field	Value	Language
dc.contributor.author	Axmedov X.S., Raximov S.S.	-
dc.date.accessioned	2025-11-11T12:08:28Z	-
dc.date.available	2025-11-11T12:08:28Z	-
dc.date.issued	2025	-
dc.identifier.citation	Andijon	en_US
dc.identifier.issn	2992-8958	-
dc.identifier.uri	http://repo.tma.uz/xmlui/handle/1/2344	-
dc.description.abstract	Ushbu tadqiqotda ankilozlovchi spondiloartrit bilan ogʻrigan bemorlarda IL-17 ingibitori Sekukinumab 150 mg bilan davolashning 12 haftadan keyin klinik samaradorligi tahlil qilindi. Bunda davolashning 12-hafta yakunida klinik samadorlik berishi bilan izohlanib, bunda kasallikning klinik yaxshilanishi (ASAS 50), ogʻriq sindromini kamayishi va umurtqa pogʻonasida funksional imkoniyatlarning kengayishi va hayot sifatini yaxshilanishi kuzatiladi. Shu bilan bir qatorda, sekukinumab qoʻllanilishi <4тD8кE <ет4лпDоте8=474 9-туD8=8=7 (MMP-9) miqdorini kamayishiga olib keladi.	en_US
dc.language.iso	other	en_US
dc.relation.ispartofseries	UO'K;616.711-002.72-007.274 -085	-
dc.subject	ankilozlovchi spondiloartrit, Sekukinumab, MMP-9.	en_US
dc.title	Anikilozlovchi spondiloartritda matriks metalloproteinaza 9-turining davo negizida o’zgarishi	en_US
dc.type	Article	en_US
Appears in Collections:	Articles

Files in This Item:

File	Description	Size	Format
Axmedov X.S., Raximov S.S..pdf	Anikilozlovchi spondiloartritda matriks metalloproteinaza 9-turining davo negizida o’zgarishi	4.04 MB	Adobe PDF	View/Open

DSpace JSPUI